Latest Conference Articles

Coexisting BRAF/TERT Mutations Predict Aggressive Thyroid Cancer

Coexisting mutations in BRAF and TERT may be associated with an aggressive phenotype and higher recurrence rates for patients with locally advanced well-differentiated thyroid cancers.

Nodule Size Should Not Determine Biopsy Decision in Thyroid Cancer

The recent American Thyroid Association guidelines to abstain from cytological evaluation by biopsy for patients with thyroid cancer on the basis of having thyroid nodules ≤1 cm is not advisable.

Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.

Pazopanib's Activity in Thyroid Cancer Not Predicted by Thyroglobulin

Pazopanib demonstrated significant clinical activity for patients with RAI-refractory differentiated thyroid cancer; however, a predictive biomarker for the therapy could not be uncovered.

Tumor Profiling Identifies Potential Biomarkers for Vandetanib in MTC

Researchers have identified molecular markers in medullary thyroid cancer that were associated with response to vandetanib and the development of metastases.

Dr. Stephen Huang on Challenges in Pediatric Thyroid Cancer

Stephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.

Vemurafenib/Sorafenib Combo Shows Promise in Papillary Thyroid Carcinoma

Dual targeting of BRAF V600E–positive papillary thyroid carcinoma with the anti-BRAF V600E agent vemurafenib and the angiogenesis inhibitor sorafenib showed promising clinical activity.

Dr. Brose on Lenvatinib in Differentiated Thyroid Cancer

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.

Radiation Underutilized in Low-Grade Follicular Lymphoma

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Dr. Valderrabano on Understanding Cancer Risk in Indeterminate Thyroid Nodules

Pablo Valderrabano, MD, Clinical Research Fellow at Moffitt Cancer Center, discusses molecular markers in thyroid nodules and their connection to cancer incidence.

Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer

Aditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

Second-Line Cabozantinib Effective in RAI-Refractory DTC

The oral multikinase inhibitor cabozantinib showed promise as a second- or third-line therapy in patients with advanced radioactive iodine-refractory differentiated thyroid cancer.

Lenvatinib PFS Benefit in DTC Maintained Across Metastasis Sites

The progression-free survival benefit with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer was observed across common sites of metastasis.

Survey Reveals Potential Overuse of Thyroid Nodule Biopsy

A large survey of endocrinologists found wide variation in management strategies for thyroid nodules that were frequently misaligned with current guidelines, particularly for biopsies by fine-needle aspiration.

Dr. Umamaheswar Duvvuri on Impact of Multiple Genetic Mutations in Advanced Thyroid Cancer

Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.

Dr. Manisha Shah on Cabozantinib Impact on Tumor Shrinkage in Differentiated Thyroid Cancer

Manisha Shah, MD, Professor of Oncology at Ohio State University Medical Center, College of Medicine discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.

Dr. Kunz on Potential of Immunotherapy in Neuroendocrine Tumors

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Everolimus Shows Robust Activity in Lung/GI NETs

Everolimus improved progression-free survival by 7.1 months compared with placebo in patients with lung/gastrointestinal (GI) neuroendocrine tumors, representing a 52% reduction in the risk of progression or death.

Lu-Dotatate Shows Unprecedented PFS in Midgut NETs

Lu-Dotatate demonstrated an unprecedented 79% reduction in the risk of progression or death compared with high-dose octreotide LAR in patients with progressive, metastatic midgut neuroendocrine tumors.

Dr. Yao on the RADIANT-4 Study for NETs of Lung or GI Origin

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses results of the RADIANT-4 study, which examined the safety and efficacy of everolimus in advanced nonfunctional neuroendocrine tumors (NETs) of lung or gastrointestinal origin.

Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid Syndrome

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.

Novel Drug Relieves Carcinoid Syndrome Symptoms

Telotristat etiprate, a novel serotonin synthesis inhibitor, helped reduce daily bowel movements for patients with carcinoid syndrome no longer responding to standard-of-care therapies.

Combining Chemo With mTOR Inhibitors Shows Promise in pNETS

Combining the chemotherapy streptozotocin with drugs that target the mTOR pathway may be an effective way to treat pancreatic neuroendocrine tumors.

Biomarker Needed for CAPTEM Regimen in Metastatic Pancreatic NETs

The efficacy of several predictive markers previously thought to determine which patients might respond to temozolomide-based therapy could not be validated for patients with pancreatic neuroendocrine tumors.

Dr. Strosberg on NETTER-1 Trial Results for Midgut NETs

Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.

Full Surgical Resection Should Be Performed Whenever Possible for Gastroenteropancreatic NETs

Full surgical resection of gastroenteropancreatic neuroendocrine tumors is associated with a greater than 90% survival rate at five years.

Dr. Liu on Medical Advancements for Neuroendocrine Tumors

Eric Liu, MD, FACS, surgeon, neuroendocrine tumors, Rocky Mountain Cancer Centers, discusses some of the most recent medical advancements in the field of neuroendocrine tumors.

Dr. Metz on Increasing Incidence of Neuroendocrine Tumors

David C. Metz, MD, gastroenterologist, University of Pennsylvania School of Medicine, associate chief, Medical Affairs, Division of Gastroenterology, discusses the increasing incidence of neuroendocrine tumors.

Dr. Poortmans on Impact of Multidisciplinary Approach on Side Effect Management

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

Dr. Lambertini on Preserving Ovarian Function and Fertility During Chemotherapy Treatment

Matteo Lambertini, MD, Department of Medical Oncology, U.O. Oncologia Medica A, Hospital San Martino, Genova, Italy, discusses the use of luteinizing hormone-releasing hormone agonists (LHRHa) during chemotherapy to preserve ovarian function and fertility in patients with breast cancer.